FETROJA (cefiderocol) for the Treatment of Bacterial Pneumonia | #klebsiella pneumoniae infections Drugs Development Market

اخبار و سیاست

FETROJA (cefiderocol) for the Treatment of Bacterial Pneumonia

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It

Examining the Challenges Facing the Medical Device Industry | #medical devices industry

دیگر

Examining the Challenges Facing the Medical Device Industry

The global medical devices M&A market saw six M&A deals in Q3 2022 with a deal size greater than $1 billion, compared to five such deals in the previous quarter. The medical devices sector M&A deals report provides a detailed analysis of M&A deals based on deal volume and v

Elotuzumab – Anti-CS1 Antibody for Multiple Myeloma | #cells Expressing T Cell Surface Glycoprotein CD5 Drugs Development Market

اخبار و سیاست

Elotuzumab – Anti-CS1 Antibody for Multiple Myeloma

Cells Expressing T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1/Leu 1 or CD5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Cells Expressing T Cell Surface Glycoprotein CD5 (Lymphocyte Ant

Trikafta/Kaftrio continues to be a game-changer for cystic fibrosis patients | #cystic Fibrosis Drugs market

اخبار و سیاست

Trikafta/Kaftrio continues to be a game-changer for cystic fibrosis patients

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung

Incyte and Eli Lilly may have JAK inhibitor edge over Pfizer for Covid-19 | #janus Kinase Drugs Development market

دیگر

Incyte and Eli Lilly may have JAK inhibitor edge over Pfizer for Covid-19

Janus Kinase (JAK or EC 2.7.10.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Janus Kinase (JAK or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information comp